Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2009-4.0-3 | Award Amount: 11.70M | Year: 2010
Medical diagnosis is currently undergoing a major revolution due to the fast discovery of molecular biomarkers, and the development of multimodal metabiomarker signatures. Progress, however, is hindered by low abundance of many biomarkers of interest in body fluids, in absolute concentration and with regard to other biomolecules. The aim of the present project is to apply these progresses in biotechnology, nanoparticle synthesis, and nano-instrumentation to the development of fully integrated lab-on chip instruments able to perform elaborate multimodal biomarker analysis on a routine basis and at the ultrasensitive level required to allow minimally invasive tests. In particular, we aim at overcoming a major bottleneck on the path to this objective, which was identified in a previous project in the HEALTH priority: no satisfactory solution currently exists to bridge the several orders of magnitude between the nanoscale volumes at which ultrasensitive new generation sensors operate, and the often millilitre volumes of samples in which the molecules of interest must be found. For this, we shall combine innovations in pre-concentration, micro and nanofluidics, self-assembly, micro-nanofabrication, and nanodetection. The project will develop a generic, multipurpose, platform of compatible enabling technologies, and integrate them into devices. In order to maximize impact and societal benefit, the project will be validated on an application of major interest for health, namely the early detection of biomarkers for neurodegenerative diseases (including Alzheimer), with special emphasis on subtyping of these diseases for improved treatment strategies. The consortium includes a multidisciplinary group of technology developers, three leading biomedical groups in clinical neuroscience for definition of specifications and end-user pre-clinical validation, and three research-oriented SMEs in biotechnology, nanosensing and microfluidics.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.4.1-2 | Award Amount: 3.91M | Year: 2008
In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of personalized medicine approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers interest and investments, the rate of introduction of novel biomarkers in clinical practice is extremely disappointing. The main aim of DECanBio is to implement a strategy for protein biomarker discovery and validation relying on the use of state of the art mass spectrometry instrumentation for quantitative analysis of proteins. For the first time, the potential of MRM-Mass Spectrometry (MRM-MS) will be tested in the scope of a large scale validation protocol of cancer protein biomarkers. This analysis will be performed in parallel to the application of miniaturized high-throughput ELISA tests for protein quantification. DECanBio strategy will be applied to issues related to bladder cancer. Specifically, a restricted number of urinary protein biomarkers enabling the detection of recurrences during the monitoring period of patients treated for bladder tumour will be validated. The work will be performed in priority for the follow-up of low-grade superficial bladder tumours (Ta stage), which, after initial resection (without BCG therapy), are likely to evolve towards remission, recurrence, or progression to a high-grade tumor. The MRM and ELISA tests developed herein aim at the high-throughput quantification of these markers in urine. Collectively, the project has the ambition to settle a whole experimental pipe-line, from the search for new bladder cancer biomarker candidates, to their thorough evaluation and validation in clinical environment. We anticipate that the tools and knowledge that will be developed here will greatly facilitate translational studies for other diseases as well.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE-2008-3-2-03 | Award Amount: 3.95M | Year: 2009
There is a growing need for effective monitoring of the micro-organisms and bioprocesses used in the sustainable production of fuels, chemicals and pharmaceuticals. The NANOBE -consortium will develop a compact, flexible analysis tool for reaction monitoring applications in the industrial biotechnology industry. The result of the NANOBE project will be an integrated measurement platform for real-time monitoring of industrial bioprocesses. This versatile platform will enable simultaneous analysis of dozens of analytes, including individual cells, product profiles and intracellular biomarkers. The platform will be composed of multiple lab-on-chip modules. Together, these modules will measure a broad range of analyte types, including small molecules, proteins, enzymes, metabolites, specific mRNAs and entire cells. The measurement platform will be a significant improvement in terms of automation, analysis time, identification and sensitivity. The analysis platform will permit real-time feedback control of large-scale production processes, screening of production organisms and optimisation of reaction conditions. The tool will improve process productivity, product quality and accelerate development of production organisms for applications in industrial biotechnology. The platform is designed to be flexible so that it can be applied either as a multiplex platform system to monitoring multiple analytes, or as individual device components for analysis of specific compounds. The versatile measurement tool will require only a change in method (e.g. a change of reagents or analysis conditions) to enable the measurement of a new analyte. The NANOBE consortium combines world-class expertise in microfluidics, nano- and microfabrication techniques, photonics, electronics, sensor technologies, and biotechnology. The platform will exploit the scaling laws associated with microfluidic devices to reduce analysis time and sample volume.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.0-1 | Award Amount: 4.18M | Year: 2013
Currently, clinical diagnosis and monitoring of bladder cancer (BC) relies on invasive, highly costly cystoscopy. Additionally, due to high recurrence rates BC treatment is associated with frequent follow-up of patients, making BC one of the most costly types of cancer in terms of management cost. Thus there is a clear clinical need for the development of new approaches for early detection of recurrence and progression. Our proposal is based on the identification of novel biomarkers (BM) for BC recurrence and progression in urine and powerful technological platforms as extensive foreground work of the involved partners in the framework of FP7 EU projects DECanBio and GENINCA. The objective of TransBioBC is to translate this foreground work in the field of BC and to specifically employ the involved technologies (CE-MS and micro-ELISA), represented by the participating SMEs, for the development of non-invasive urine tests for routine monitoring of BC recurrence and progression. Our project uniquely integrates leading BC clinical experts with experts on proteome analysis and high throughput immunoassay development in an implementation-oriented workflow. Strict monitoring of assay analytical performance, and properly collected and well characterized clinical samples from existing sufficiently powered BC cohorts are combined with in-depth knowledge of regulatory requirements, analysis approaches to define added value and well designed business plans including multi-stakeholder dissemination and exploitation plans. Collectively, TransBioBC will provide strong evidence for utility of the new BM directly in BC clinical management and as a secondary aim for usage in clinical trials and drug development.
Diagnoswiss Sa | Date: 2007-10-02
Chemical or biochemical assay apparatus, namely microfluidic chips used in chemical or biological analysis, and parts therefor.